Propulsid
(Cisapride)ApprovedSmall molecule
Propulsid is one of 64 small molecule programs targeting Gastroparesis. It is currently in Approved.
2
Indications
4
Total Trials
0
Active Trials
63
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
113 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Repatha
AmgenApproved
Coreg
Akero TherapeuticsApproved
Natrecor
SScios, Inc.
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Propulsid
WWim Janssens
Approved
Zontivity
Akero TherapeuticsApproved
Retatrutide
Eli LillyPhase 3
Zofran
NovartisPhase 2
Combination Therapy
Chong Kun Dang PharmaceuticalPhase 3
Lanoxin
AAdvanz Pharma
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastro-oesophageal Reflux Disease1 trial
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
Terminated·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT01281553·6 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT01281553·6 enrolledPremature Infants1 trial
A Study of Cisapride in Premature Infants With Feeding Problems
Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT01281566·8 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT01281566·8 enrolledDiabetes Mellitus1 trial
Gastroparesis1 trial
Regulatory
FDA Approval Timeline[4]
Jul 29, 1993
PROPULSID
NDA NDA020210
Sep 15, 1995
PROPULSID
NDA NDA020398
Nov 7, 1997
PROPULSID QUICKSOLV
NDA NDA020767
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cisapride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens